Pharmacokinetics, pharmacodynamics, and tolerability of subcutaneous administration of a novel glycoprotein IIb/IIIa inhibitor, RUC-4, in patients with ST-segment elevation myocardial infarction

Willem L. Bor, Kai L. Zheng, Anne H. Tavenier, C. Michael Gibson, Christopher B. Granger, Ohad Bentur, Rita Lobatto, Sonja Postma, Barry S. Coller, Arnoud W. J. van 't Hof, Jurrien M. Ten Berg*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)401-410
Number of pages73
JournalEurointervention
Volume17
Issue number5
DOIs
Publication statusPublished - Aug 2021

Keywords

  • 2017 ESC
  • ANTIPLATELET THERAPY
  • IMPACT
  • PERCUTANEOUS CORONARY INTERVENTION
  • PREHOSPITAL INITIATION
  • PRIMARY ANGIOPLASTY
  • STEMI
  • THROMBOCYTOPENIA
  • TICAGRELOR
  • TIROFIBAN
  • adjunctive pharmacotherapy
  • clinical research
  • clinical trials
  • innovation
  • ALPHA-IIB-BETA-3 ANTAGONIST

Cite this